PRTK - Paratek's treatment for pulmonary anthrax shows promise in study

• Paratek Pharmaceuticals ( NASDAQ: PRTK ) on Monday announced positive top line data from a pilot rabbit efficacy study evaluating NUZYRA’s (omadacycline) effectiveness in the treatment of pulmonary anthrax.
• Shares +5.3% at $1.88 in early trading session.
• In the study, a 100% survival rate was observed in NUZYRA-treated rabbits at the specified endpoint.
• Positive top line data from this study triggered the second procurement under its Project BioShield contract with BARDA.
• The company said it would recognize $38.1 million in revenue, comprised of $36.4 million from BARDA and about  $1.7 million in deferred revenue related to post-marketing commitments under the Project BioShield contract.
• Accordingly, Paratek has delivered 2,500 treatment courses of NUZYRA to BARDA.

For further details see: